Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 10, Number 1—January 2004

Research

Respiratory and Urinary Tract Infections, Arthritis, and Asthma Associated with HTLV-I and HTLV-II Infection

Edward L. Murphy*, Baoguang Wang†, Ronald A. Sacher‡, Joy Fridey§, James W. Smith¶, Catharie C. Nass#, Bruce Newman**, Helen E. Ownby**, George Garratty††, Sheila T. Hutching††, and George B. Schreiber†
Author affiliations: *University of California San Francisco, California, USA; †Westat, Rockville, Maryland, USA; ‡Hoxworth Blood Center, Cincinnati, Ohio, USA; §Blood Bank of San Bernardino and Riverside Counties, San Bernardino, California, USA; ¶Oklahoma Blood Institute, Oklahoma City, Oklahoma, USA; #American Red Cross Blood Services Chesapeake and Potomac, Baltimore, Maryland, USA; **American Red Cross Blood Services Southeastern Michigan, Detroit, Michigan, USA; ††American Red Cross Blood Services Southern California, Los Angeles, California, USA

Main Article

Table 2

Incidence of medically diagnosed conditions and selected unadjusted and adjusted incidence ratios among human T-lymphotropic virus (HTLV)-I– and HTLV-II– infected participants and HTLV-seronegative participants, visits 2 and 3a

Diagnosis HTLV seronegative (N = 799) HTLV-I (N = 152) HTLV-II (N = 387)
Cases (%b) Cases (%b) IRc Adj. IR (95% CI)d Cases (%b) IRc Adj. IR (95% CI)d
Pneumonia 25 (3) 5 (4) 0.89 0.79 (0.27 to 2.29) 19 (5) 1.70 1.82 (0.98 to 3.38)
Acute bronchitis 103 (14) 21 (15) 1.12 1.10 (0.68 to 1.79) 81 (23) 1.83 1.68 (1.24 to 2.29)
Bladder or kidney infection 105 (14) 31 (23) 1.74 1.82 (1.19 to 2.77) 73 (21) 1.68 1.55 (1.14 to 2.11)
Arthritis 32 (5) 16 (16) 3.19 2.84 (1.51 to 5.33) 32 (12) 2.51 2.66 (1.58 to 4.45)
Hypertension 40 (7) 7 (7) 1.06 0.99 (0.44 to 2.22) 20 (7) 1.08 1.09 (0.63 to 1.89)
Asthma 15 (2) 2 (2) 20 (6) 3.38 3.28 (1.57 to 6.84)
Cancer 21 (3) 3 (2) 0.81 0.72 (0.21 to 2.43) 8 (2) 0.87 1.10 (0.44 to 2.32)

aOnly the first diagnosis of each condition is considered for each participant. IR, incidence ratio derived from survival analysis; CI, confidence interval.
bDenominator for percentage calculation varied according to the number of participants included in each disease-specific analysis.
cUnadjusted incidence ratio derived from survival analysis.
dAfter a backward selection process, including all potential confounding variables, the final survival analysis model contained these variables age, gender, race/ethnicity, and (for pneumonia, bronchitis, and asthma) smoking history (see Methods for details of the statistical analysis).

Main Article

TOP